130 related articles for article (PubMed ID: 25297512)
1. Polymorphism in CYP2D6 and CYP2C19, members of the cytochrome P450 mixed-function oxidase system, in the metabolism of psychotropic drugs.
Stingl J; Viviani R
J Intern Med; 2015 Feb; 277(2):167-177. PubMed ID: 25297512
[TBL] [Abstract][Full Text] [Related]
2. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.
Bertilsson L; Dahl ML; Dalén P; Al-Shurbaji A
Br J Clin Pharmacol; 2002 Feb; 53(2):111-22. PubMed ID: 11851634
[TBL] [Abstract][Full Text] [Related]
3. CYP2D6 variation, behaviour and psychopathology: implications for pharmacogenomics-guided clinical trials.
Peñas-Lledó EM; Llerena A
Br J Clin Pharmacol; 2014 Apr; 77(4):673-83. PubMed ID: 24033670
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of CYP2C19 and CYP2D6 metabolic activity on antidepressant response from 13 clinical studies using genotype imputation.
Li D; Pain O; Fabbri C; Wong WLE; Lo CWH; Ripke S; Cattaneo A; Souery D; Dernovsek MZ; Henigsberg N; Hauser J; Lewis G; Mors O; Perroud N; Rietschel M; Uher R; Maier W; Baune BT; Biernacka JM; Bondolfi G; Domschke K; Kato M; Liu YL; Serretti A; Tsai SJ; Weinshilboum R; ; ; McIntosh AM; Lewis CM
medRxiv; 2023 Dec; ():. PubMed ID: 37425775
[TBL] [Abstract][Full Text] [Related]
5. Do we need pharmacogenetics to personalize antidepressant therapy?
Lanni C; Racchi M; Govoni S
Cell Mol Life Sci; 2013 Sep; 70(18):3327-40. PubMed ID: 23272319
[TBL] [Abstract][Full Text] [Related]
6. [The relationship of cytochrome P450 isoforms with the efficacy and safety of antipsychotic and antidepressant therapy].
Bairamova SP; Pavlova OV; Shport SV; Gurina OI; Pavlov KA
Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(11):40-46. PubMed ID: 37994887
[TBL] [Abstract][Full Text] [Related]
7. Which can Predict the Outcome of Antidepressants: Metabolic Genes or Pharmacodynamic Genes?
Zheng N; Niu M; Zang Y; Zhuang H; Jia F; Bao S; Liu S
Curr Drug Metab; 2023; 24(7):525-535. PubMed ID: 37691197
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetic Guidelines for Psychotropic Drugs: Optimizing Prescriptions in Clinical Practice.
Baldacci A; Saguin E; Balcerac A; Mouchabac S; Ferreri F; Gaillard R; Colas MD; Delacour H; Bourla A
Pharmaceutics; 2023 Oct; 15(11):. PubMed ID: 38004520
[TBL] [Abstract][Full Text] [Related]
9. How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?
Carvalho Henriques B; Yang EH; Lapetina D; Carr MS; Yavorskyy V; Hague J; Aitchison KJ
Front Genet; 2020; 11():491895. PubMed ID: 33363564
[TBL] [Abstract][Full Text] [Related]
10. Editorial: The pros and cons of psychotropic drug-induced changes in periphery and central nervous system: elucidating structural and molecular mechanisms.
Esposito R; Cai H; Guo W; Dai H; Jiang P
Front Psychiatry; 2023; 14():1269307. PubMed ID: 38045620
[No Abstract] [Full Text] [Related]
11. CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants.
Haufroid V; Hantson P
Clin Toxicol (Phila); 2015 Jul; 53(6):501-10. PubMed ID: 25998998
[TBL] [Abstract][Full Text] [Related]
12. Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations.
LLerena A; Naranjo ME; Rodrigues-Soares F; Penas-LLedó EM; Fariñas H; Tarazona-Santos E
Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1569-83. PubMed ID: 25316321
[TBL] [Abstract][Full Text] [Related]
13. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.
Hicks JK; Bishop JR; Sangkuhl K; Müller DJ; Ji Y; Leckband SG; Leeder JS; Graham RL; Chiulli DL; LLerena A; Skaar TC; Scott SA; Stingl JC; Klein TE; Caudle KE; Gaedigk A;
Clin Pharmacol Ther; 2015 Aug; 98(2):127-34. PubMed ID: 25974703
[TBL] [Abstract][Full Text] [Related]
14. Clinical perspective on the Clinical Pharmacogenetics Implementation Consortium Updated 2014 guidelines for CYP2D6 and codeine.
Nicholson WT; Formea CM
Clin Chem; 2015 Feb; 61(2):319-21. PubMed ID: 25301855
[No Abstract] [Full Text] [Related]
15. Pharmacogenetic prediction of individual variability in drug response based on CYP2D6, CYP2C9 and CYP2C19 genetic polymorphisms.
Chaudhry SR; Muhammad S; Eidens M; Klemm M; Khan D; Efferth T; Weisshaar MP
Curr Drug Metab; 2014; 15(7):711-8. PubMed ID: 25429673
[TBL] [Abstract][Full Text] [Related]
16. Molecular study of weight gain related to atypical antipsychotics: clinical implications of the CYP2D6 genotype.
Nussbaum LA; Dumitraşcu V; Tudor A; Grădinaru R; Andreescu N; Puiu M
Rom J Morphol Embryol; 2014; 55(3):877-84. PubMed ID: 25329115
[TBL] [Abstract][Full Text] [Related]
17. Polymorphic expression of CYP2C19 and CYP2D6 in the developing and adult human brain causing variability in cognition, risk for depression and suicide: the search for the endogenous substrates.
Ingelman-Sundberg M; Persson A; Jukic MM
Pharmacogenomics; 2014; 15(15):1841-4. PubMed ID: 25495406
[No Abstract] [Full Text] [Related]
18. Distribution of CYP2D6 alleles and phenotypes in the Brazilian population.
Friedrich DC; Genro JP; Sortica VA; Suarez-Kurtz G; de Moraes ME; Pena SD; dos Santos AK; Romano-Silva MA; Hutz MH
PLoS One; 2014; 9(10):e110691. PubMed ID: 25329392
[TBL] [Abstract][Full Text] [Related]
19. Effect of CYP2C9, CYP4F2 and VKORC1 genetic polymorphisms on pharmacokinetics and pharmacodynamics of mean daily maintenance dose of warfarin in Chinese patients.
Zhuang W; Wen W; Xuan B; Chen Y; Cao Y; Sun Z; Ma J
Blood Coagul Fibrinolysis; 2015 Mar; 26(2):167-74. PubMed ID: 25304014
[TBL] [Abstract][Full Text] [Related]
20. Effect of Cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors.
Probst-Schendzielorz K; Viviani R; Stingl JC
Expert Opin Drug Metab Toxicol; 2015; 11(8):1219-32. PubMed ID: 26028357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
